METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES

• US 20110237602A1
• Filed: 03/28/2011
• Published: 09/29/2011
• Est. Priority Date: 03/29/2010
• Status: Active Grant

• Current Assignee: Sumitomo Pharmaceuticals Company Limited (Sumitomo Chemical Company Limited), Vanderbilt University
• Original Assignee: Dainippon Sumitomo Pharma Company Limited (Sumitomo Chemical Company Limited), Vanderbilt University
• Inventors: Horiguchi, Masakuni, MELTZER, Herbert Y.
• Granted Patent: US 8,735,397 B2
• Time in Patent Office: Days
• US Class Current: 514/254.04
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants

Abstract

The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.

Claims

1. A method for treating schizophrenia and/or bipolar disorder which comprises administering a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof, and a therapeutically effective amount of a mGluR2 ligand to a mammal in need thereof.

2. The method of claim 1 wherein the mGluR2 ligand is a mGluR2 agonist.

3. The method of claim 1 wherein the mGluR2 ligand is a mGluR2 positive allosteric modulator.

4. The method of claim 1 wherein the mGluR2 ligand is one or more selected from the group consisting of LY404039, LY2140023, LY379268, LY354740 (eglumegad), LY354740 monohydrate, TS-032, AZD-8529, ADX71149, MGS-0008, MGS-0028, MGS-0039, MGS-0210, BINA, LY487379, and pharmaceutically acceptable salts thereof.

5. A pharmaceutical product for treating schizophrenia and/or bipolar disorder which comprises a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof, and a therapeutically effective amount of a mGluR2 ligand.

6. A method for improving cognitive impairment associated with schizophrenia which comprises administering a therapeutically effective amount of lurasidone or a pharmaceutically acceptable acid addition salt thereof, and a therapeutically effective amount of a mGluR2 ligand to a mammal in need thereof.